Adherex Technologies (FENC) Competitors $8.68 +0.15 (+1.70%) As of 07/3/2025 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FENC vs. MLYS, PHVS, NRIX, ORIC, MDXG, PRAX, LENZ, CRMD, OCS, and RCUSShould you be buying Adherex Technologies stock or one of its competitors? The main competitors of Adherex Technologies include Mineralys Therapeutics (MLYS), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Oric Pharmaceuticals (ORIC), MiMedx Group (MDXG), Praxis Precision Medicines (PRAX), LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), and Arcus Biosciences (RCUS). These companies are all part of the "med - biomed/gene" industry. Adherex Technologies vs. Its Competitors Mineralys Therapeutics Pharvaris Nurix Therapeutics Oric Pharmaceuticals MiMedx Group Praxis Precision Medicines LENZ Therapeutics CorMedix Oculis Arcus Biosciences Mineralys Therapeutics (NASDAQ:MLYS) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends. Does the media prefer MLYS or FENC? In the previous week, Mineralys Therapeutics had 4 more articles in the media than Adherex Technologies. MarketBeat recorded 4 mentions for Mineralys Therapeutics and 0 mentions for Adherex Technologies. Mineralys Therapeutics' average media sentiment score of 0.47 beat Adherex Technologies' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mineralys Therapeutics Neutral Adherex Technologies Neutral Which has higher earnings & valuation, MLYS or FENC? Adherex Technologies has higher revenue and earnings than Mineralys Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.89Adherex Technologies$47.54M5.04-$440K-$0.51-17.03 Do insiders and institutionals have more ownership in MLYS or FENC? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 25.6% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 11.8% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MLYS or FENC? Mineralys Therapeutics presently has a consensus price target of $32.25, suggesting a potential upside of 122.03%. Adherex Technologies has a consensus price target of $13.00, suggesting a potential upside of 49.68%. Given Mineralys Therapeutics' higher probable upside, research analysts plainly believe Mineralys Therapeutics is more favorable than Adherex Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Adherex Technologies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more volatility and risk, MLYS or FENC? Mineralys Therapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Is MLYS or FENC more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -45.52%. Adherex Technologies' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -71.15% -65.71% Adherex Technologies -45.52%N/A -26.37% SummaryAdherex Technologies beats Mineralys Therapeutics on 8 of the 15 factors compared between the two stocks. Get Adherex Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$239.71M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-17.0321.5627.6020.30Price / Sales5.04172.94369.09103.84Price / Cash264.4341.9536.6357.47Price / Book-41.367.518.055.68Net Income-$440K-$55.05M$3.18B$249.13M7 Day Performance5.27%4.61%2.82%3.30%1 Month Performance13.09%4.89%3.70%5.20%1 Year Performance44.03%5.84%35.41%21.38% Adherex Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCAdherex Technologies1.7611 of 5 stars$8.69+1.7%$13.00+49.7%+44.0%$239.71M$47.54M-17.03N/AMLYSMineralys Therapeutics2.1906 of 5 stars$13.53-1.3%$32.25+138.4%+19.5%$893.55MN/A-3.6328PHVSPharvaris1.3636 of 5 stars$17.60+3.5%$36.20+105.7%+10.4%$888.93MN/A-5.8530NRIXNurix Therapeutics1.5282 of 5 stars$11.39-2.1%$30.18+164.9%-34.4%$887.38M$54.55M-4.07300Trending NewsUpcoming EarningsAnalyst RevisionORICOric Pharmaceuticals4.1604 of 5 stars$10.15-1.6%$19.17+88.8%+43.2%$878.66MN/A-5.4380MDXGMiMedx Group3.4461 of 5 stars$6.11+2.9%$12.50+104.6%-7.8%$877.35M$348.88M22.63870PRAXPraxis Precision Medicines3.1802 of 5 stars$42.05-2.2%$109.90+161.4%+18.2%$875.87M$8.55M-3.92110LENZLENZ Therapeutics1.3528 of 5 stars$29.31-2.9%$46.60+59.0%+84.2%$849.45MN/A-16.56110CRMDCorMedix2.6206 of 5 stars$12.32-1.4%$17.14+39.1%+181.8%$847.81M$43.47M56.0030Analyst RevisionHigh Trading VolumeOCSOculis1.7874 of 5 stars$19.41+0.3%$35.33+82.0%+62.0%$844.87M$780K-7.352RCUSArcus Biosciences2.8687 of 5 stars$8.17+2.8%$21.29+160.5%-41.1%$841.79M$258M-1.95500 Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Oric Pharmaceuticals Alternatives MiMedx Group Alternatives Praxis Precision Medicines Alternatives LENZ Therapeutics Alternatives CorMedix Alternatives Oculis Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adherex Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adherex Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
